Home World News A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients... World News A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 637 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Why consistent and funded cancer policies are key to improving cancer... November 1, 2022 RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... April 18, 2023 Research with integrity – why building networks is vital for integrity March 22, 2023 Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... April 9, 2025 Load more HOT NEWS Can Some People with Breast Cancer Safely Skip Lymph Node Radiation? The Cancer Moonshot: Moving from Planning to Research Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In...
